UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.